Pneumonia, Ventilator-Associated
61
6
6
31
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
14.8%
9 terminated out of 61 trials
77.5%
-9.1% vs benchmark
21%
13 trials in Phase 3/4
32%
10 of 31 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 31 completed trials
Clinical Trials (61)
Tobramycin Nebulization to Prevent Multidrug-Resistant Ventilator-Associated Pneumonia
Immunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia
BIS in ICU Interventional Study
Automated Oxygen Administration in Patients With Hypoxemic Pneumonia and Pleuropneumonia
Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Immunocompromised Patients With Hospital-acquired Pneumonia Requiring Mechanical Ventilation
Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients
Biomarkers for Ventilator-associated Pneumonia
TRacheal Cuff PRessure Evaluation Study
The Efficacy of Adjuvant Oral Care in Prevention of Ventilator Associated Pneumonia.
Study Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia
Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Patients With Hospital-acquired Pneumonia
Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients
Predicting Ventilator-associated Lower Respiratory Tract Infection Outcomes Using Sequenced-based Early Microbiological Response
Lung Ultrasound-guided Fluid Therapy in Pediatric Intensive Care Unit Patients
PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region
Preoperative Optimization to Improve Functional Status
Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia
FilmArray Pneumonia Panel for Antimicrobial Treatment of HAP/VAP in Intensive Care Units
Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301
CTTI Risk Factors for HABP/VABP Study